RETISERT IMPLANT

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

FLUOCINOLONE ACETONIDE

Предлага се от:

BAUSCH & LOMB INC

АТС код:

S01BA15

INN (Международно Name):

FLUOCINOLONE ACETONIDE

дозиране:

0.59MG

Лекарствена форма:

IMPLANT

Композиция:

FLUOCINOLONE ACETONIDE 0.59MG

Начин на приложение:

INTRAVITREAL

Броя в опаковка:

15G/50G

Вид предписание :

Prescription

Терапевтична област:

CORTICOSTEROIDS

Каталог на резюме:

Active ingredient group (AIG) number: 0106314003; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2008-03-13

Данни за продукта

_0.59 mg Retisert Product Monograph _
_Page 1 of 36 _
PRODUCT MONOGRAPH
PR
RETISERT
TM
Fluocinolone acetonide
0.59 mg
Intravitreal Implant
ATC Code: S01BA15
Bausch & Lomb Incorporated
1400 N Goodman Street
Rochester, NY 14609
USA
Imported by:
Bausch & Lomb Canada Inc.
520 Applewood Crescent
Vaughan, Ontario
L4K 4B4
Date of Preparation:
March 12, 2013
Control No.: 156472
_0.59 mg Retisert Product Monograph _
_Page 2 of 36 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
..........................................................................................
4
ADVERSE REACTIONS
............................................................................................................
8
DRUG INTERACTIONS
..........................................................................................................
20
DOSAGE AND ADMINISTRATION
......................................................................................
21
OVERDOSAGE
.........................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
22
STORAGE AND STABILITY
..................................................................................................
23
SPECIAL HANDLING INSTRUCTIONS
...............................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 23
PART II: SCIENTIFIC INFORMATION
................................................................................
24
PHARMACEUTICAL INFORMA